講演・口頭発表等 - 森瀬 昌宏
-
IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC 国際共著 国際会議
Herbst Roy, De Marinis Filippo, Giaccone Giuseppe, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos, Morise Masahiro, Font Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Mocci Simonetta, McCleland Mark, Enquist Ida, Komatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Spigel David
JOURNAL FOR IMMUNOTHERAPY OF CANCER 2020年4月
-
Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC 国際共著 国際会議
Reinmuth Niels, Spigel David, De Marinis Filippo, Giaccone Giuseppe, Verynenegre Alain, Barrios Carlos Henrique, Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozgueroglur Mustafa, Mocci Simonetta, Mccleland Mark, Enquist Ida, Kotnatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Herbst Roy S.
ONCOLOGY RESEARCH AND TREATMENT 2020年2月
-
Impact Of Mild To Moderate COPD On Prognosis And Feasibility For Chemotherapy In Patients With Lung Cancer
Omote N., Hashimoto N., Morise M., Miyazaki S., Ando A., Hasegawa Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2017年
-
Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT 国際会議
Tamiya Y., Morise M., Matsuzawa R., Tanaka I., Okada T., Iwano S., Hase T., Hashimoto N., Sato M., Itoh Y., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2019年10月
-
Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status 国際会議
Koyama Junji, Kimura Tomoki, Oi Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Matsuzawa Reiko, Fukihara Jun, Sakamoto Koji, Morise Masahiro, Hashimoto Naozumi, Kondoh Yasuhiro, Hasegawa Yoshinori
ANNALS OF ONCOLOGY 2019年10月
-
Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen 国際会議
Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2017年11月
-
Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC). 国際会議
Seto Takashi, Nishio Makoto, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Kim Young Hak, Azuma Koichi, Takiguchi Yuichi, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Tamura Tomohide
JOURNAL OF CLINICAL ONCOLOGY 2019年5月20日
-
eIF2 beta, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer 国際会議
Goto D., Tanaka I., Sato M., Kato T., Miyazawa A., Hase T., Morise M., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2018年10月
-
Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung 国際会議
Morise Masahiro, Hishida Tomoyuki, Takahashi Akiko, Yoshida Junji, Ohe Yuichiro, Nagai Kanji, Ishii Genichiro
JOURNAL OF THORACIC ONCOLOGY 2017年1月
-
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study 国際共著 国際会議
Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D. R., Jassem J.
ANNALS OF ONCOLOGY 2019年12月
-
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 国際共著 国際会議
Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D., Jassem J.
SWISS MEDICAL WEEKLY 2020年11月18日
-
Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) 国際会議
Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.
JOURNAL OF THORACIC ONCOLOGY 2019年10月
-
Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC 国際共著 国際会議
Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.
ANNALS OF ONCOLOGY 2020年9月
-
Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study 国際会議
Park K., Felip E., Veillon R., Cortot A., Mazieres J., Sakai H., Reinmuth N., Viteri S., Chen Y-M., Han J-Y., Jang T-W., Morise M., Sakamoto T., Tokito T., Cho B. C., Bruns R., Scheele J., Straub J., Le X., Paik P. K.
ANNALS OF ONCOLOGY 2019年11月
-
Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer 国際会議
Oi H., Yamano Y., Yokoyama T., Matsuda T., Morise M., Kataoka K., Kimura T., Kondoh Y.
ANNALS OF ONCOLOGY 2019年11月
-
UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer 国際会議
Goto D., Kizuki M., Uwatoko N., Kawai K., Koike M., Nakashima M., Miyazawa A., Tanaka I., Hase T., Morise M., Hasegawa Y., Minna J., Sato M.
JOURNAL OF THORACIC ONCOLOGY 2019年10月
-
The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer 国際会議
Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori
CANCER SCIENCE 2018年12月
-
Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A 国際共著 国際会議
Mazieres J., Paik P., Felip E., Veillon R., Sakai H., Cortot A., Viteri S., Garassino M., Van Meerbeeck J., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.
JOURNAL OF THORACIC ONCOLOGY 2021年1月
-
Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data 国際共著 国際会議
Sakai H., Felip E., Cortot A. B., Veillon R., Griesinger F., Patel J., Horn L., Mazieres J., De Castro Carpeno J., Morise M., Sakamoto T., Bruns R., Scheele J., Straub J., Paik P.
ANNALS OF ONCOLOGY 2018年11月
-
Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A 国際共著 国際会議
Mazieres J., Paik P. K., Felip E., Veillon R., Sakai H., Cortot A. B., Viteri S., Garassino M. C., Van Meerbeeck J. P., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.
ANNALS OF ONCOLOGY 2020年9月